{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:33:04Z","timestamp":1771644784967,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.mehy.2016.12.004","type":"journal-article","created":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T12:20:38Z","timestamp":1482063638000},"page":"23-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Is insulin growth factor-1 the future for treating autism spectrum disorder and\/or schizophrenia?"],"prefix":"10.1016","volume":"99","author":[{"given":"Rami","family":"Bou Khalil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2016.12.004_b0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(09)61376-3","article-title":"Autism","volume":"374","author":"Levy","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2016.12.004_b0010","article-title":"Early IGF-1 primes visual cortex maturation and accelerates developmental switch between NKCC1 and KCC2 chloride transporters in enriched animals","author":"Baroncelli","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2016.12.004_b0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1362361313514141","article-title":"Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study","volume":"19","author":"Hadjikhani","year":"2015","journal-title":"Autism"},{"key":"10.1016\/j.mehy.2016.12.004_b0020","doi-asserted-by":"crossref","first-page":"101R","DOI":"10.1203\/PDR.0b013e318212c177","article-title":"Theory of mind and neurodevelopmental disorders of childhood","volume":"69","author":"Korkmaz","year":"2011","journal-title":"Pediatr Res"},{"key":"10.1016\/j.mehy.2016.12.004_b0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2010.11.031","article-title":"Is schizophrenia on the autism spectrum?","volume":"1380","author":"King","year":"2011","journal-title":"Brain Res"},{"key":"10.1016\/j.mehy.2016.12.004_b0030","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/scan\/nst114","article-title":"Default mode network connectivity and reciprocal social behavior in 22q11.2 deletion syndrome","volume":"9","author":"Schreiner","year":"2014","journal-title":"Soc Cogn Affect Neurosci"},{"key":"10.1016\/j.mehy.2016.12.004_b0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/WNF.0000000000000136","article-title":"Treating schizophrenia with the diuretic bumetanide: a case report","volume":"39","author":"Lemonnier","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.mehy.2016.12.004_b0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.mehy.2011.06.001","article-title":"Recombinant human IGF-1 for patients with schizophrenia","volume":"77","author":"Bou Khalil","year":"2011","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2016.12.004_b0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2040-2392-5-38","article-title":"Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders","volume":"5","author":"Wesseling","year":"2014","journal-title":"Mol Autism"},{"key":"10.1016\/j.mehy.2016.12.004_b0050","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/glia.22584","article-title":"The PTEN inhibitor bisperoxovanadium enhances myelination by amplifying IGF-1 signaling in rat and human oligodendrocyte progenitors","volume":"62","author":"De Paula","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.mehy.2016.12.004_b0055","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1017\/S0012162206001605","article-title":"Cerebrospinal fluid insulin-like growth factors IGF-1 and IGF-2 in infantile autism","volume":"48","author":"Riikonen","year":"2006","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.mehy.2016.12.004_b0060","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.mehy.2013.01.010","article-title":"Insulin-like growth factor and the etiology of autism","volume":"80","author":"Steinman","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2016.12.004_b0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng1933","article-title":"Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders","volume":"39","author":"Durand","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.mehy.2016.12.004_b0070","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1073\/pnas.0906232107","article-title":"De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia","volume":"107","author":"Gauthier","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2016.12.004_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2040-2392-4-9","article-title":"Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay","volume":"4","author":"Bozdagi","year":"2013","journal-title":"Mol Autism"},{"key":"10.1016\/j.mehy.2016.12.004_b0080","first-page":"5073078","article-title":"Illness severity, social and cognitive ability, and EEG analysis of ten patients with Rett Syndrome treated with Mecasermin (Recombinant Human IGF-1)","volume":"2016","author":"Pini","year":"2016","journal-title":"Autism Res Treat"},{"key":"10.1016\/j.mehy.2016.12.004_b0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00787-012-0255-z","article-title":"Would some cannabinoids ameliorate symptoms of autism?","volume":"21","author":"Bou Khalil","year":"2012","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.mehy.2016.12.004_b0090","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1073\/pnas.1118167109","article-title":"Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors","volume":"109","author":"den Boon","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2016.12.004_b0095","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/db12-0901","article-title":"Developmental role for endocannabinoid signaling in regulating glucose metabolism and growth","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.mehy.2016.12.004_b0100","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.neubiorev.2013.02.013","article-title":"Cannabis, psychosis and the thalamus: a theoretical review","volume":"37","author":"Vukadinovic","year":"2013","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.mehy.2016.12.004_b0105","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.2174\/13816128113199990427","article-title":"Cannabinoids and schizophrenia: therapeutic prospects","volume":"20","author":"Robson","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2016.12.004_b0110","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00417-014-2917-7","article-title":"Regulation of surface expression of TRPV2 channels in the retinal pigment epithelium","volume":"253","author":"Reichhart","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.mehy.2016.12.004_b0115","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.mehy.2016.12.004_b0120","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.aad5487","article-title":"CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency","volume":"351","author":"Bidinosti","year":"2016","journal-title":"Science"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716304170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716304170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T20:23:59Z","timestamp":1536179039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716304170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":24,"alternative-id":["S0306987716304170"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2016.12.004","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is insulin growth factor-1 the future for treating autism spectrum disorder and\/or schizophrenia?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}